Movement Alert|Veradermics, Inc. Falls 4.37% in Regular Trading, Market Continues to Digest Q3 Results, Clinical Updates and Recent Target Hikes

Market Focus11-13 23:12

On November 13, Veradermics, Inc. fell 4.37% in Regular Trading to $129.26 per share, with turnover of $12.28 million.

The move came as the market continued to digest the company’s recently reported third-quarter results, clinical progress for VDPHL01 and updated analyst views, even after several firms raised price targets.

Veradermics, Inc. reported a third-quarter net loss of $21.0 million, wider than the $20.1 million loss a year earlier but better than the $26.5 million loss expected by analysts, with no revenue reported. Cash, cash equivalents and marketable securities stood at $798.4 million at September 30, which management said should fund operations into 2030. On the clinical side, VDPHL01 met co-primary efficacy endpoints in two registration-directed male pattern hair loss studies, while initial topline data from the female registration-directed trial are expected in the first half of 2027. Separately, Leerink maintained a Buy rating and raised its price target to $185.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment